Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more
Whitehawk Therapeutics, Inc. (WHWK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.098x
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has a cash flow conversion efficiency ratio of -0.098x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.38 Million) by net assets ($157.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Whitehawk Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Whitehawk Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lonyer Fuels
SHG:603003
|
0.026x |
|
LX Hausys Ltd Preferred
KO:108675
|
0.096x |
|
Azkoyen
MC:AZK
|
0.141x |
|
CI Games SA
WAR:CIG
|
0.044x |
|
Exotic Food Public Company Limited
BK:XO
|
0.107x |
|
Cingulate Inc
NASDAQ:CING
|
-1.222x |
|
Creepy Jar SA
WAR:CRJ
|
0.029x |
|
Agencia Comercial Spirits Ltd Class A Ordinary Shares
NASDAQ:AGCC
|
N/A |
Annual Cash Flow Conversion Efficiency for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +22.50% |
| 2019-12-31 | $-9.09 Million | $-7.58 Million | 0.834x | -- |